tbuckley/cabot-search huggingface dataset:
Abstract 3701: Better Preservation of Left Atrial Systolic Force By Losartan may Contribute to Lower Incidence of New-onset Atrial Fibrillation: The LIFE study
Authors: Kristian Wachtell, Marcello Chinali, Michael H Olsen, Giovanni de Simone, Eva Gerdts, Björn Dahlöf, Richard B Devere
Journal: Circulation (2006)

Background: In hypertensive patients enhanced left atrial (LA) systolic force (LASF), a recently-introduced measure of active LA function, is associated with LV hypertrophy and increased preload. H...
Clinical Features and Treatment Outcome of Children With Myeloid Antigen Positive Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group
Authors: Fatih M. Uckun, Harland N. Sather, Paul S. Gaynon, Diane C. Arthur, Michael E. Trigg, David G. Tubergen, James Nachman, Peter G. Steinherz, Martha G. Sensel, Gregory H. Reaman
Journal: Blood (1997)
Correlation of 1-125 lothalamate and Tc-99m DTPA Measurements of GFR Using the Single Injection Method
Authors: STEPHEN N. WIENER, YOGESH P. SHAH, RANDOLPH M. MARES, MICHAEL J. FLYNN
Journal: Clinical Nuclear Medicine (1982)

Simultaneous renal imaging and determination of GFR can be obtained using Tc-99m DTPA. In order to assess the accuracy of the GFR value, a comparison was made between commercial sources of Tc-99m DTPA and I-125 iothalamate. The calculation assumed monoexponential loss of each radiopharmaceutical from the renal compartment. Plasma measurements were made at two sampling intervals, 90 to 120 minutes and 180 to 240 minutes. An apparent volume of distribution calculated for plasma concentrations at 2 hours and 3 hours was examined as a single sample indication of GFR. GFR values appear to be higher with DPTA than with iothalamate at the earlier interval. Choice of the later sampling times may be desirable for patients with known renal disease. The apparent volume of distribution at 3 hours may be a convenient single sample for monitoring or surveying patients for renal disease.
Abstract 4042: Epidemiology of Inflammatory and Non-inflammatory Dilated Cardiomyopathy: Initial Assessement From the KNHI Demonstrate Underdiagnosis of Inflammatory and Familial Cardiomyopathy
Authors: Bernhard Maisch, Goetz Gelbrich, Thomas Scheffold, Heribert Schunkert, P Binner, Anette Richter, Sabine Pankuweit
Journal: Circulation (2009)
A hair as the nucleus of an appendicular calculus
Authors: Athelstan Saw
Journal: BMJ (2001)

The habit of biting one's moustache is one seemingly unattended with danger, but that it may lead to disastrous consequences the following experience of mine will show. I had occasion some few weeks ago to operate on J. T. H., a private patient, for recurrent attacks of appendicitis, the last one of which was of a severe type. At the …
Preventing headache after lumbar puncture
Authors: A. Sharma, E. Williams, W. Fawcett, G. Jenkins, C. Sudlow, M G Serpell, G J Haldane, D R S Jamieson, D Carson
Journal: BMJ (1998)

Editor—Serpell et al’s survey of lumbar puncture practice in the United Kingdom reminds us that small (22-26 gauge), atraumatic needles, which reduce the incidence of headache after lumbar puncture, are not being routinely used.1 The incidence of headache after lumbar puncture is roughly 35% with 20 gauge standard needles, 5% with 22 gauge atraumatic needles, and 1% with 25 gauge atraumatic needles.2 Adequate cerebrospinal fluid can be obtained by aspirating with smaller needles. The cost of an atraumatic (Whitacre or Sprotte) needle is about £4, compared with £1 for the standard (Quincke) needle. Using 22 gauge atraumatic needles would therefore cost £10 per headache prevented. A third of headaches after lumbar puncture are described as severe, prolonged, or debilitating and unresponsive to simple measures.3 Prolonged headache after lumbar puncture can lead to subdural haematoma.4

The authors mention that epidural blood patching is a successful way of treating persistent headache after lumbar puncture. Epidural blood patching is widely used by anaesthetists for the more severe headache after lumbar puncture caused accidentally by large 16 gauge or 18 gauge epidural needles.5

I conducted an audit at a district general hospital that performs about 150 lumbar punctures annually. Only three out of 26 doctors were aware of the option of epidural blood patching for headache after lumbar puncture (eight junior house officers, 10 middle grade doctors, and eight consultant or staff grade doctors were surveyed). In addition, less than half (of all grades) were able to state correctly the characteristic features of headache after lumbar puncture—fronto-occipital distribution, relief when the patient lies down, onset up to several days after dural puncture, and duration up to several weeks. Clearly, these points still need to be disseminated to all those who perform and teach how to perform lumbar puncture. This is an important message that is equally relevant to surgeons, obstetricians, and general practitioners who encounter headache after lumbar puncture or spinal or epidural anaesthesia.
Abstract 5459: Vascular Endothelial Nuclear Factor-{kappa}B Contributes to Endothelial Dysfunction Via Oxidative Stress in Middle-Aged and Older Overweight/Obese Humans
Authors: Gary L Pierce, Lisa A Lesniewski, Brooke R Lawson, Stacy D Beske, Douglas R Seals
Journal: Circulation (2008)

We recently reported that vascular endothelial NFκB, a key proinflammatory nuclear transcription factor associated with the development of atherosclerosis, modulates endothelial dysfunction (impair...
Abstract 8559: Efficacy of Implantable Cardiac Defibrillators for the Prevention of Sudden Cardiac Death in Patients with Cardiac Sarcoidosis
Authors: Jordana Kron, Frank M Bogun, Thomas C Crawford, Sinan H Sarsam, Davendra Mehta, Arnold J Greenspon, Matthew Ortman, David B DeLurgio, Ravinder R Valadri, Calambur Narasimhan, Swapna Nalla, Jagmeet P Singh, Stephan B Danik, David G Benditt, Adrian K Almquist, Andrew D Krahn, Joshua M Cooper, Steven M Markowitz, Jacquelene Morales, Luke G Wolfe, Shawn D Feinstein, Kenneth A Ellenbogen
Journal: Circulation (2011)

Introduction Patients with cardiac sarcoidosis (CS) are at increased risk for sudden death from ventricular arrhythmias. There is little evidence regarding the efficacy and safety of implantable cardiac defibrillators (ICDs) in this population. Hypothesis Data on demographic, clinical, and ICD intervention history was retrospectively collected on 138 CS patients with ICDs from 11 academic centers throughout the U.S., Canada, and India. We hypothesized that patients with CS would have a high incidence of appropriate ICD therapies. Results Sixty-two of 138 CS patients (44.92%) had an appropriate ICD therapy (ATP or shock) with 39 patients (28.3%) receiving 5 or more therapies (Figure). Forty-eight of 131 patients (36.64%) received an appropriate shock. Thirty-seven of 136 patients (27.21%) had an inappropriate shock. The incidence of appropriate therapy (ATP or shock) was 10.4%/year and the incidence of appropriate shock was 8.5%/year. Twenty-two patients (15.9%) experienced an adverse event, the most common being lead dislodgement in 11 patients (8%). Appropriate therapies (ATP or shock) were more common in patients with syncope 24/37 (65%) versus patients who did not have syncope 38/101 (38%) (p = 0.0065). Appropriate therapies were more common in patients who had ventricular pacing on baseline EKG, 9/10 (90%), compared with those who did not, 53/128 (41%) (p=0.0053). The mean age of patients who received an appropriate therapy (n=59) was 51.7 ± 11.6 compared with 56.9 ± 10.2 for those who did not receive appropriate therapy (n=74) (p = 0.0066). Immunosuppressive medications including steroids, methotrexate, azathioprine, and hydroxychloroquine were not associated with reduced number of appropriate therapies. Conclusions Patients with CS have high rates of appropriate ICD therapies. This population also has high rates of inappropriate shocks and adverse events. Syncope, ventricular pacing, and younger age may identify the highest risk CS patients.
Abstract 2014: Outcome and Characteristics of Out-of-Hospital Pediatric Cardiac Arrest from the large-scale, population-based Utstein Osaka cohort study
Authors: Masahiko Nitta, Taku Iwami, Naoki Shimizu, Robert A Berg, Takashi Kawamura, Toshimasa Hayashi, Kentaro Kajino, Tatsuya Nishiuchi, Yasuyuki Hayashi, Atsushi Hiraide, Hisashi Ikeuchi, Hiroshi Nonogi, Hiroshi Tamai, Hiroshi Morita, J-Pulse investigators
Journal: Circulation (2007)
Abstract 17043: Severe Pulmonary Hypertension in Young Adults with Coarctation of the Aorta Repaired in Infancy.
Authors: Pastora Gallego, Ana E Gonzalez, M Carmen Gomez-Rubin, Antonio J Carton, Angel Sanchez-Recalde, Sandra Villagra, Clara Salas, Angel Aroca, Jose M Oliver
Journal: Circulation (2010)
Unchanging Pattern of Pulmonary Tuberculosis
Authors: S GRZYBOWSKI, W B MARR
Journal: JAMA (1963)

Study of mortality from pulmonary tuberculosis in Ontario between 1881 and 1961 reveals a steady decline in rates since the beginning of this century, affecting both sexes and all age groups. This decline has been much faster in the younger than in the older age groups. When the mortality rates are studied for groups of men and women born within 10-year periods (10-year cohorts) an orderly pattern of mortality emerges, consisting of two distinct phenomena. First, the shape of the "cohort" curves is always similar: the mortality rates rise sharply in childhood and the peak is reached in early adult life, followed by a gradual descent. This appears to be a basic but unexplained feature of pulmonary tuberculosis. Secondly, each cohort shows through its life span a lower mortality rate than the previous cohort, but a higher rate than the succeeding one; it is suggested that this is primarily due to a decline in intensity of tuberculous infection over the past several decades. The high tuberculosis rates seen now in the elderly are but the residue of the much higher rates experienced by these people early in their lives.
Abstract 17370: Perceptions of Patients with Stable Coronary Disease and Adherence to Dual Antiplatelet Therapy 30-Days after Coronary Angiography
Authors: Michelle M Fennessy, Catherine Ryan, Holli DeVon, Bryant H Nguyen, John J Lopez, Julie Zerwic
Journal: Circulation (2011)

Background : Platelet inhibition is an important focus of medical management in patients with stable coronary artery disease (CAD), with multiple patient-related factors linked to dual antiplatelet therapy (DAPT) non-adherence. However, little is known about illness perceptions surrounding the use of antiplatelet medications and whether they differ in patients who are treated with medical and/or interventional approaches. The purpose of this study was to compare differences in illness perceptions of patients with stable CAD and report adherence to DAPT 30 days after initiating treatment. Methods : Subjects ( n =180) were recruited after coronary angiography and optimal medical therapy (OMT) ( n =90) and percutaneous coronary intervention and optimal medical therapy (PCI/OMT) ( n =90). The Illness Perception Questionnaire-Revised (IPQ-R) was administered at baseline and 30-days after treatment, with a response rate of 52.8% ( n =95) at 30-days. Patients were predominantly male (71.7%) with a mean age of 65.1 (±8.3). Adherence to DAPT (aspirin and thienopyridine) at 30-days was collected using a health history update. Results : Adherence data (mean ± SEM) and IPQ-R subscale Timeline scores are shown . Adherent PCI/OMT subjects had significantly higher acute/chronic timeline (aspirin: t =-3.5, p =.01; thienopyridine: t =-4.3, p =&lt;.001) and timeline cyclical scores (aspirin t =-2.5, p =.01; thienopyridine: t =-2.8, p =.009). Conclusions : Overall, patients who perceived their illness to be chronic instead of acute were more likely to remain adherent to their antiplatelet medications 30 days after treatment. Higher timeline cyclical scores were reported in patients who were adherent to antiplatelet medications after PCI/OMT, which suggests the influence of continued symptoms as an indicator for adherence. A tailored educational approach regarding dual-antiplatelet medications may be needed to reinforce long-term therapy in this population of patients.
Abstract 591: Can Waveform Characteristics Predict Defibrillation to a Perfusing Rhythm in Short Versus Prolonged Ventricular Fibrillation in a Swine Model?
Authors: Julia H Indik, Mathias Zuercher, Karl B Kern, Ronald W Hilwig, Robert A Berg
Journal: Circulation (2008)

It is known that defibrillation of ventricular fibrillation (VF) to a perfusing rhythm (ROSC) is more likely to occur in VF of short duration. It is unknown whether ROSC can be predicted by waveform characteristics in VF of short compared to long duration, apart from a consideration of time alone. VF was untreated for 2 minutes (N=10) or 8 minutes (N=10) in normal swine, after which a defibrillation shock was applied. Chest compressions for two minutes were allowed following but not prior to the shock to achieve a perfusing rhythm (ROSC). VF was analyzed from needle electrodes prior to the shock for amplitude spectral area (AMSA), slope, median frequency and bandwidth. Predictors of ROSC were determined by logistic regression. In VF of 2 minute duration 7 out of 10 swine achieved ROSC compared to 2 out 10 swine with VF of 8 minutes (P=0.025) and time was a significant predictor of ROSC (P=0.033). AMSA was significantly higher at 2 minutes (75 ± 18 mV-Hz) compared to 8 minutes (56±11 mV-Hz, p=0.007) as was slope (3.5±1 vs 2.6±0.5 mV/s, p=0.015). Bandwidth was slightly increased from 2.2±0.6 Hz at 2 minutes to 2.8±0.8 Hz at 8 minutes,(p=0.048), while median frequency was similar. However, no waveform characteristic was a significant predictor of ROSC, with substantial overlap in distributions between animals with and without ROSC. Duration of VF is an important determinant of the likelihood of achieving ROSC with defibrillation. Particularly in VF of short duration, VF waveform characteristics do not add to the predictability of achieving ROSC even though they may demonstrate a significant time evolution.
Abstract 10214: Coronary Artery Anatomy in Congenital Heart Disease with Posterior Aorta: Medical and Surgical Implications
Authors: Meng-Luen Lee, Ing-Sh Chiu, Shu-Chien Huang
Journal: Circulation (2011)

Background: Since Van Praagh's report of transposition of the great arteries (TGA) with posterior aorta, it is well known that this entity, with aortopulmonary rotation (APR) >right lateral 90°, us...
PX-171–006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): Preliminary results
Authors: R. Niesvizky, W. Bensinger, M. Vallone, A. Gutierrez, L. Kunkel
Journal: Journal of Clinical Oncology (2009)

8541 Background: CFZ is a highly specific proteasome inhibitor with single agent activity in relapsed/refractory MM (ASH 2008). The purpose of this study is to evaluate the safety and activity of CFZ in combination with LEN and loDex. Methods: This phase Ib trial evaluates 4 dose levels (≥ 3 pts each) to define the maximum tolerated dose (MTD) of CFZ/LEN/loDex in relapsed/refractory MM pts who failed 1–3 prior therapies, including prior LEN or bortezomib (BTZ). CFZ IV 15- 20 mg/m 2 (d1,2,8,9,15,16), LEN 10–20 mg po (d1–21) and loDex 40 mg po (d1, 8, 15, 22) in 28-day cycles (C). An additional 10–15 pts will be evaluated at the highest dose level reached. Dose limiting toxicity (DLT) has been defined as grade (G) ≥ 3 non- hematologic; G4 neutropenia for &gt; 7d and/or neutropenic fever; G4 thrombocytopenia &gt; 7d or G3-G4 thrombocytopenia in association with bleeding. Overall response (CR/sCR, VGPR/PR) is assessed by IWG criteria, with secondary assessment by modified EBMT criteria which includes MR. Results: 11 pts have been enrolled. 8/11 are evaluable for response and toxicity. Median prior lines of therapy was 2 (range 2–3). Prior therapies included DEX (8/8), BTZ (6/8), LEN (7/8), alkylators (6/8), anthracyclines (5/8), stem cell transplant (5/8), and thalidomide (1/8); 6/8 pts had received both LEN and BTZ. MTD has not yet been reached after the first 2 dose cohorts. No drug related SAEs or G3/4 treatment emergent AEs were reported. Responses to date with a median of 2 C (range 1–4) are shown below. Responses were rapid and occurred within the first 28-day cycle. Conclusions: CFZ/LEN/loDex in combination was well tolerated in the first 2 cohorts. There have been no myleosuppressive or renal DLTs. The combination has achieved early encouraging responses in pts who had failed both LEN and BTZ at doses well below the single agent MTD of either LEN or CFZ. Dose escalation is ongoing. Updated data will be presented at the meeting. [Table: see text] [Table: see text]
Analysis of Ritonavir for the Treatment of HIV Disease in Children
Authors: James M. Oleske
Journal: JAMA (1998)

Background:Ritonavir, a potent antiretroviral protease inhibitor, has been approved for the treatment of adults and children with human immunodeficiency virus (HIV) infection. In a phase I/II study, we assessed the safety, tolerability, and pharmacokinetic profile of the oral solution of ritonavir in HIV-infected children and studied the preliminary antiviral and clinical effects.Methods:HIV-infected children between 6 months and 18 years of age were eligible. Four dose levels of ritonavir oral solution (250, 300, 350, and 400 mg/m2 given every 12 hours) were evaluated in two age groups (≤2 years, &gt;2 years). Ritonavir was administered alone for the first 12 weeks and then in combination with zidovudine and/or didanosine. Clinical and laboratory parameters were monitored every 2 to 4 weeks.Results:A total of 48 children (median age, 7.7 years; range, 0.5 to 14.4 years) were included in this analysis. Dose-related nausea, diarrhea, and abdominal pain were the most common toxicities and resulted in discontinuation of ritonavir in 7 children. Ritonavir was well absorbed at all dose levels, and plasma concentrations reached a peak 2 to 4 hours after a dose. CD4 cell counts increased by a median of 79 cells/mm3 after 4 weeks of monotherapy and were maintained throughout the study. Plasma HIV RNA decreased by 1 to 2 log10 copies/mL within 4 to 8 weeks of ritonavir monotherapy, and this level was sustained in patients enrolled at the highest dose level of 400 mg/m2 for the 24-week period.Conclusions:The oral solution of ritonavir has potent antiretroviral activity as a single agent and is relatively well tolerated by children when administered alone or in combination with zidovudine or didanosine.
Abstract 2982: Incidence of Myocardial Infarction or Stroke or All-Cause Mortality in Patients with Severe Carotid Arterial Disease Treated with and without Statins
Authors: Wilbert S Aronow, Gautham Ravipati, Chul Ahn, Venu Channamsetty, Vishal Sekhri
Journal: Circulation (2006)

Purpose: To investigate the incidence of myocardial infarction (MI) or stroke or all-cause mortality in patients with severe carotid arterial disease not revascularized treated with and without statins.  Methods: During a 5-year period, 449 patients (59% men), mean age 72 ± 10 years, with > 70% narrowing of 1 or 2 carotid arteries not revascularized were followed for the incidence of new MI or new stroke or all-cause mortality. Of the 449 patients, 298 (66%) were treated with statins. The mean age, gender, and prevalence of smoking, hypertension, diabetes mellitus, prior MI, and prior stroke were not significantly different between patients treated with and without statins. A serum total cholesterol ≥ 200 mg/dl was present in 298 of 298 patients (100%) treated with statins and in 145 of 151 patients (96%) not treated with statins (p   Results: MI or stroke or death occurred in 45 of 298 patients (15%) treated with statins and in 102 of 151 patients (68%) not treated with statins (p   Conclusion: Statins significantly reduced the incidence of new MI or new stroke or death in patients with severe carotid arterial disease and hypercholesterolemia not treated with revascularization.
Abstract 414: Impact of Aging on the Normal Right Ventricle: A Cardiovascular Magnetic Resonance Study
Authors: Garima Arora, Philmon Gona, Carol J Salton, Michael L Chuang, Rahul R Jhaveri, Christopher J O'Donnell, Warren J Manning
Journal: Circulation (2009)

Background: Cardiovascular magnetic resonance (CMR) is considered the non-invasive gold standard for assessment of the right ventricle (RV). Age-specific CMR reference values for RV mass (RVM), end...
DVD Offers Mold Remediation Tips
Authors: Tanya Tillett
Journal: Environmental Health Perspectives (2007)

extent of contamination."The CDC based some of its findings on a landmark 2004 report, Damp Indoor Spaces and Health, by the Institute of Medicine (IOM) of the National Academies.Relying on the IOM report, and dozens of studies and reports that have been published since, many organizations and individuals that must deal regularly with mold problems have begun to take steps to reduce the threat.But many of the puzzle pieces-exactly who is vulnerable, to what extent, and under what conditions-are still missing.The vast information gaps that remain continue to feed significant controversy in the legal, insurance, political, scientific, medical, public health, and building design, construction, management, and maintenance arenas.
Abstract 17152: Identification and Site-Specific Quantification of Novel Phosphorylated Residues in Cardiac Troponin I: Implications for Heart Failure
Authors: Pingbo Zhang, Anne M Murphy, Jennifer E Van Eyk
Journal: Circulation (2010)

Cardiac Troponin I (cTnI), a key regulatory and inhibitory myofilament protein, is known to be phosphorylated at six residues (Ser23/24, Ser42/44, Thr143, Ser150) by PKA, PKC, PKD, PKG and PAK etc. Although it is known that phosphorylation levels are altered in heart failure (HF) the exact sites involved are yet to be determined. Using the state-of-the-art targeted proteomic technique-multiple reaction monitoring (MRM) assay, we aimed to develop multiplex quantification in failing and non-failing human LV samples for all sites. Myofibril cTnIs were purified and identified from the banked end-stage HF with Ischemic Heart Disease (ISHD) and Idiopathic Cardiomyopathy (IDCM) patients and compared with non-failing hearts (n=30). Overall, we identified 12 phosphorylation sites including 6 novel sites: Ser4/5, Try26, Ser77, Ser166, Thr181 and Ser199. To quantify phosphorylation status of each site, total 30 assays and 145 transitions were designed for each mono or di-phosphorylated and the corresponding non-phosphorylated sequence and analyzed by 4000 Qtrap nano-LC-MS/MS in triplicate. Status on sites Ser4/5, Try26and Ser24 was significantly reduced in ISHD (↓42.2±0.7%; ↓67.2±0.6%, p<0.005) and IDCM (↓49.4±0.5%, p<0.001; ↓88.3±0.2%, p<0.005) patients compared with non-failing donors. However, phosphorylation in HF was higher on novel sites Ser77(ISHD ↑48.9±1.9% and IDCM ↑38.4±1.5, p<0.005); Ser166(ISHD ↑34.4±0.3% and IDCM ↑206.3±0.5%, p<0.01); Thr181(ISHD↑35.0±0.3% and IDCM ↑32.9±0.2%, p<0.001), Ser199 (ISHD ↑167.7±0.1%, p<0.005 and IDCM ↑133.3±0.1%, p<0.001) and the known Ser42 (ISHD ↑40.8±0.8% and IDCM ↑49.1±0.7%, p<0.005) and Thr143 (ISHD ↑10.1±0.8% and IDCM ↑11.7±0.7%, p<0.001) as compared to donor heart. In summary, this study provides the first identification and quantification of 6 novel phosphorylated sites. With HF there is i) a shift in the phosphorylation from PKA to PKC sites; ii) importantly shift with decreased in the N-terminal residues Ser4/5, 24 and Try26 and increased with the middle Ser77, Ser166, Thr181 and C-terminal Ser199. Thus, dynamic and selective alterations occurred to individual residues of cTnI most likely reflecting changes in the upstream signaling cascades eg. imbalance in kinase/phosphatase activity.